Sino Biopharmaceutical Limited
SBMFF
$0.9891
$0.03914.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.44% | 10.31% | 7.54% | 5.91% | 83.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.44% | 10.31% | 7.54% | 5.91% | 83.25% |
| Cost of Revenue | -- | -- | 5.88% | 4.28% | -- |
| Gross Profit | -- | -- | 7.91% | 6.28% | -- |
| SG&A Expenses | -- | -- | 6.43% | 4.82% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 8.47% | 6.83% | -- |
| Total Operating Expenses | 19.12% | 20.08% | 6.74% | 5.13% | 86.72% |
| Operating Income | -28.96% | -28.40% | 10.50% | 8.82% | 70.67% |
| Income Before Tax | -- | -- | 14.50% | 12.77% | -- |
| Income Tax Expenses | -- | -- | 19.32% | 17.52% | -- |
| Earnings from Continuing Operations | -- | -- | 13.56% | 11.85% | -- |
| Earnings from Discontinued Operations | -- | -- | 985.02% | 968.60% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -6.76% | -5.15% | -- |
| Net Income | -54.86% | -54.50% | 131.93% | 128.42% | 133.61% |
| EBIT | -28.96% | -28.40% | 10.50% | 8.82% | 70.67% |
| EBITDA | -- | -19.17% | 5.36% | 3.77% | -- |
| EPS Basic | -55.00% | -52.50% | 135.42% | 128.00% | 135.29% |
| Normalized Basic EPS | -- | -- | 52.94% | 52.94% | -- |
| EPS Diluted | -55.00% | -52.50% | 135.42% | 128.00% | 166.67% |
| Normalized Diluted EPS | -- | -- | 52.94% | 52.94% | -- |
| Average Basic Shares Outstanding | -1.89% | -- | -0.84% | -0.84% | -0.30% |
| Average Diluted Shares Outstanding | -1.88% | -1.70% | -0.83% | -0.83% | -2.02% |
| Dividend Per Share | 36.84% | 36.84% | 46.15% | 35.71% | -44.12% |
| Payout Ratio | -- | -- | -- | -- | -0.46% |